Innate Immunity, Toll-Like Receptors, and Diabetes

Marcia F. McInerney*1, Lindsey A. Alexander1, Michael P. Morran2 and Massimo Pietropaolo2

1College of Pharmacy, Department of Medicinal and Biological Chemistry, Center for Diabetes and Endocrine Research, University of Toledo, Toledo, Ohio, USA
2Laboratory of Immunogenetics, The Brehm Center for Type 1 Diabetes and Analysis, Division of Metabolism, Endocrinology & Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA

Abstract: Innate immunity is the first line of defense in guarding the host against foreign pathogenic invaders. Cells of the innate immune system express pattern recognition receptors, such as toll-like receptors (TLRs), that recognize common molecular patterns of bacteria and viruses. However, along with the recognition of foreign pathogens, TLRs have also been shown to respond to endogenous substrates including; RNA released from dead or dying cells, oxidized molecules such as low density lipoproteins, and free fatty acids. When TLRs are triggered, signal transduction occurs resulting in increased expression and production of various cytokines and costimulatory molecules. TLR activation due to the recognition of self endogenous antigen has been implicated in perpetuating multiple autoimmune responses by skewing immune responses toward strong proinflammation. TLR activation can prime an adaptive immune response, potentially possessing the ability to signal the generation of autoantibodies and autoreactive lymphocytes. Therefore, TLRs, their associated signaling molecules, and their triggered cytokines, are prime candidates for future research in type 1 diabetes (T1D) and autoimmunity. Recently, inflammation has been shown to be a component of type 2 diabetes (T2D). In T2D, signaling through TLRs, in association with free fatty acids, is correlated with insulin resistance. Furthermore, TLRs and their associated signaling molecules are increased in the adipose tissue of T2D patients where inflammatory cells can accumulate. This review focuses on innate immunity and TLR involvement in both T1D and T2D. Therapeutic measures to manipulate TLR signaling, the expression of signaling components, and inflammatory cytokines may help to alleviate the disease process.

Keywords: Autoimmunity, Type 1 diabetes, Type 2 diabetes, Toll-like receptors, innate immunity.

TYPE 1 DIABETES

Type 1 diabetes (T1D) is an autoimmune disease wherein the immune system specifically targets the destruction of pancreatic insulin producing β-cells. Once insulin production is lost, the body is unable to maintain normal glucose homeostasis and glucose levels rise in the blood and urine. Thus, individuals suffering from T1D must replace insulin by injection, multiple times daily, to prevent hyperglycemia and maintain normal glucose levels.

T1D is a complex polygenic disease [1] however, only four T1D susceptibility loci have been identified with convincing and reproducible statistical support: the HLA class II genes [2], the insulin gene [3, 4], the CTLA4 locus [5, 6] and the PTPN22 [7, 8]. A recent addition to this list is the interferon-induced helicase (IFIH1) region [9]. The DR genotype associated with the highest risk for T1D is the DR3/4-DQ8, where DQ8 is the heterozygous genotype DQA1*0301, DQB1*0302 [10]. Early HLA genotyping would help to identify individuals at high risk for T1D prior to clear signs of islet autoimmunity such as islet autoantibodies.

Animal model research has illustrated that the onset of T1D occurs in a two step process characterized initially by asymptomatic inflammation or insulitis, followed by autoimmune destruction of the β-cell mass and concomitant loss of β-cell function. Cells of both the innate and adaptive immune system are found within the insulitis lesion. Macrophages (MΦ) are the first cell type to arrive followed by T-lymphocytes, B-lymphocytes, and natural killer (NK) cells [11-17]. The autoimmune destruction of the pancreatic β-cells takes place in a cell-mediated organ specific manner that requires both CD4+ and CD8+ T-cells [12, 18, 19], as well as MΦs [16-19].

In the islet microenvironment, activated MΦs are able to secrete nitrogen and oxygen free radicals, as well as various cytokines including: interleukin-1β (IL-1β), interleukin-12 (IL-12), interleukin-8 (IL-8), and tumor necrosis factor-α (TNFα) [20]. The nitrogen and oxygen free radicals can directly penetrate cells causing intracellular damage to DNA, lipids, and proteins. The cytokines TNFα and IL-1β, produced by MΦ, along with interferon-γ (IFNγ), produced by neighboring T-cells, can have a direct toxic effect on β-cells [21]. Furthermore, IL-12 from activated MΦs can enhance the ability of the adaptive immune system to generate autoreactive β-cell specific cytotoxic T-cells in the NOD mouse. Alternately, loss of MΦ function leads to prevention of T1D in animal models [22-24]. These results indicate that activated MΦs can directly damage β-cells as well as lead to indirect β-cell damage by activating other cell types.

Once the innate immune system has been activated within the pancreas an adaptive immune response is subsequently triggered, generating autoreactive T-cells, B-cells, and antibodies. As pancreatic material is destroyed and diabetes progresses, the number of autoantigens targeted by T-
cells as well as autoantibodies can increase [25]. This phenomenon is called epitope spreading and is observed in autoreactive T-cells that recognize islet self-antigens (insulin, glutamic acid decarboxylase (GAD), 65 kDa isofrom, ICA512/IA-2 and I-A2β) and the autoreactive B-cells which generate the corresponding autoantibodies [25]. Therefore, both the innate and adaptive immune system and the interactions between them are involved in the development of diabetes. This review will also focus on the receptors and signaling molecules, utilized by the innate immune system, to examine their role in autoimmune and inflammatory diseases such as T1D.

**TYPE 2 DIABETES**

Type 2 diabetes (T2D) is a disease of insulin resistance, meaning that normally insulin-sensitive tissues such as liver, skeletal muscle, adipose, and the pancreas no longer respond to increasing amounts of insulin in the blood, which normally stimulates cellular uptake of glucose. Research has shown that an accumulation of Mφs, in hypertrophic adipose tissue of obese animals and humans, plays an important role in the development and/or worsening of insulin resistance and T2D. Two mechanisms of MΦ infiltration into white adipose tissue (WAT) have been suggested [26, 27]. Paracrine and endocrine signaling of cytokines and chemokines can draw blood monocytes towards adipose, stimulated by mechanical modifications such as adipocyte hypertrophy and hyperplasia, which can activate local endothelial cells to favor monocyte attachment and transmigration leading to MΦ infiltration. Alternately, local hypoxia may trigger chemotaxis of MΦs, as it is known that MΦs play a role in angiogenesis [26]. Once in the hypertrophied adipose tissue, MΦs phagocytize dead and dying cells. Several studies provided evidence suggesting that the infiltrated MΦs are derived from bone marrow [28] and are not differentiated pre-adipocytes which, in an inflammatory environment, do have some macrophage-like functions and similarities in gene expression profiles [26, 27].

Excised adipose tissue from obese animals can be enzymatically separated into two fractions, 1) mature adipocytes and 2) the stromal vascular cells (SVCs) comprised of MΦs, dendritic cells (DCs), and other lymphocytes (possible with inflammation), pre-adipocytes, fibroblasts, and endothelial cells. MΦs and DCs are known for their extensive inflammatory cytokine secretion capabilities, as well as for their roles as professional antigen presenting cells (APC). These inflammatory cytokines can have both autocrine and paracrine functions that affect local cell types such as adipocytes, pre-adipocytes, and endothelial cells, along with endocrine systemic effects, which can have negative effects on other organs and body systems. Notably, inflammatory cytokines are involved in the pathogenesis of atherosclerosis and non-alcoholic steatohepatitis (NASH) or fatty liver disease [29]. Both of these two adipose tissue fractions have been shown to secrete varying levels of TNFα and macrophage chemotactic protein-1 (MCP-1), also known as chemokine CCL2, while the SVCs are the main producers of inflammatory interleukins, such as IL-6, inducible nitric oxide synthase (iNOS), and C-reactive protein (CRP). Although adipocytokines, such as leptin, adiponectin, and resistin, additionally play a role in obesity and diabetes, these molecules will not be addressed in this review article.

Inflammatory cytokine levels often correlate with insulin resistance severity [26, 27, 30]. TNFα, in particular, is known to affect insulin sensitivity in insulin target tissues such as liver and skeletal muscle, by interfering with insulin signaling [31, 32]. Serum of type 2 diabetic patients have elevated levels of acute-phase proteins, such as TNFα and IL-6 [26, 27, 30, 33-35]. There is a positive correlation between body mass index (BMI) and CRP, an inflammatory indicator [27]. Correspondingly, weight loss reduces inflammatory markers and associated complications [26, 27]. A further consequence of inflammatory cytokines and a contributing factor to insulin resistance, is the release of free fatty acids (FFA) via lipolysis of adipocytes both locally and into circulation. Therefore, inflammation and the innate immune system appear to play a role in T2D, as well as being the common thread between T1D and T2D.

**TOLL-LIKE RECEPTORS**

Innate immunity is the body’s first line of defense against pathogenic microbes and is comprised of multiple cell types including: MΦs, DCs, natural killer (NK) cells, neutrophils, eosinophils, and mast cells [36]. Each cell type is capable of mediating specific functions in an innate immune response, from the phagocytosis of infectious pathogens to the direct targeted lysis of infected host cells [37].

The toll-like receptor (TLR) family, which is comprised of 13 members (TLR1-TLR13), plays a key role in pathogen recognition by the innate immune system [38]. TLRs are involved in innate immune responses, but also play a role in shaping adaptive immune responses through primary recognition of infectious pathogens [39, 40]. Although beneficial in host defense, TLRs have also been implicated in a number of diseases including T1D [41-43], as well as being involved in secondary complications associated with both T1D and T2D [44, 45].

TLRs are pathogen recognition receptors (PRR) that recognize molecules commonly expressed by infectious pathogens, known as pathogen associated molecular patterns (PAMPs), that are not expressed by the mammalian host [46]. Unlike adaptive immune system receptors, PRRs are not clonal receptors and are unable to clonally expand [38-40, 47]. Structurally, TLRs are type I integral membrane glycoproteins consisting of leucine rich repeats in the extracellular domain and a TIR (Toll/ IL-1R) cytoplasmic domain [38, 40]. As PRRs, the TLRs recognize many PAMPs including microbial membrane derived molecules via TLR4 and TLR2, bacterial flagellin via TLR5, as well as DNA and RNA from bacteria and viruses via TLRs 3, 7, 8, and 9 [38, 40, 47-49]. TLRs 1, 2, 4, 5, and 6 are expressed on the cell surface, whereas TLRs 3, 7, 8, and 9 are found within intracellular compartments such as endosomes [47].

The small number of innate immune receptors faces a large and diverse set of pathogens. In order to compensate, TLRs often recognize more than a single type of molecule. For instance, TLR2 responds to lipoteichoic acid and peptidoglycan from gram positive bacteria and lipoproteins of gram negative bacteria. TLR4 binds not only lipopolysaccharide of gram negative bacteria, but also envelope proteins of...
some viruses, (reviewed in [38]). Lipopolysaccharide (LPS) from various pathogens are heterogeneous and stimulate TLR4 with various efficiencies [50]. Furthermore, subtypes of LPS have complex interactions including inhibiting the responses of others [51]. TLRs regulate and cross-regulate their own expression and signaling. TLR4 and TLR2 develop tolerance and are downregulated by a repeated exposure to a strong activating antigen [52]. TLR3 is upregulated by its ligand dsRNA [53], but at the same time can induce endotoxin tolerance by downregulating TLR4 [54].

TLRs can also recognize endogenous antigens or self molecules expressed by the host [49], especially if the molecules are indicators of stress or disease [55]. Furthermore, some self molecules, directly modified by the disease process, can become neoantigens to the immune system. At sites of oxidative stress or inflammation, breakdown of extracellular matrix components [56] or oxidation [57] can occur, resulting in conversion of self molecules into agonists of TLR activation. For example, free fatty acids, oxidized low density lipoprotein (LDL), and non-esterified fatty acids are endogenous ligands for TLR2 and TLR4 in inflammatory disease states [58]. TLR4 recognizes heat shock protein (HSP60), an endogenous product of inflammation, while both TLR2 and TLR4 are required for recognition of self-protein HSP70 [38, 55]. mRNA originating from damaged tissue, necrotic cells, or endocytosed cells is an endogenous protein HSP70 [38, 55]. In particular, endogenous RNA released in necrotic synovial fluid can activate synovial fibroblasts in human rheumatoid arthritis via TLR3 [60].

The demand on host defense to protect against a large number of pathogenic microbes has to be balanced by the need to simultaneously spare the host, despite inherent cross reactivity and complex signaling patterns. In all probability, these conflicting interests must be met by a precise combinatorial tuning of the recognition, and the response of, both PAMPs and self-antigens. Such a fine balance can easily be disturbed by pathophysiological conditions during disease.

**TLR SIGNALING**

Ligand binding to a specific TLR initiates signal transduction that leads to cellular activation. TLR signaling molecules are similar to those used in the interleukin-1 receptor (IL-1R) signaling cascade [47]. Although TLRs recognize a variety of ligands, most TLRs utilize the adaptor protein myeloid differentiation factor 88 (MyD88) to initiate internal cell signaling. However, once internalized, multiple activation pathways exist for TLRs [47]. Signal transduction results in an up-regulation of the gene expression and protein production of numerous inflammatory Th1 cytokines, chemokines, and costimulatory molecules. This enhances innate immune cell sensitivity by promoting antigen presentation and activation of the adaptive immune system [38, 61-64].

A simplified model of TLR signaling and activation of cytokines and co-stimulatory molecules is presented in Fig. (I). TLRs 1, 2, 4, 5, 6, 7, 8, 9, and 11 promote cell activation via the MyD88 dependent pathway. Signal transduction through MyD88 elicits the interleukin-1 receptor-associated kinase (IRAK) family. Signal transduction continues with IRAK activation of tumor necrosis factor receptor-associated factor-6 (TRAF6), which then stimulates several molecules into the formation of transforming growth factor-β-protein kinase 1 (TAK1) complex. The activated TAK1/TABs complex signals both the NF-κB essential modulator (NEMO)/ IKKs complex and the mitogen activated protein kinases (MAPKs). The NEMO/IKK complex catalyzes IkB, thus freeing nuclear factor-κB (NF-κB) subunits to translocate into the nucleus. The TAK1/TABs complex can also activate the MAPK pathway, activating protein-1 (AP-1), which becomes phosphorylated and moves into the nucleus. Both NF-κB and AP-1 control inflammatory responses through the induction of pro-inflammatory cytokines such as TNFα, IL-1β, IL-6, IL-8, IL-12 and IL-18 [64-67].

TLR3 follows a MyD88 independent pathway (reviewed in [68]). The TIR domain-containing adapter inducing IFNβ (TRIF) pathway recruits TLR3, which then interacts with the tank-binding kinase-1 (TBK-1)/IKKi complex. The TBK-1/IKKi kinases mediate phosphorylation of interferon regulatory factor-3 (IRF3), which then dimerizes and translocates to the nucleus. TRIF can, however, also interact with TRAF6 and the signal from TLR3 activation can flow through the pathways to NF-κB and AP-1. The activation of IRF3, NF-κB and MAPK pathways is required for the induction of type 1 interferons (IFN) particularly IFNβ (Fig. 1).

Uniquely, TLR4 can signal through both the MyD88 dependent pathway and the TRIF-dependent pathway. Signaling of TLR4 through MyD88 involves early phase activation of NF-κB which leads to the production of pro-inflammatory cytokines. Signaling of TLR4 through TRIF leads to IRF3 activation and late phase NF-κB activation, both of which lead to the production of IFNβ and the expression of IFN-inducible genes. MyD88 signaling through TLR7 and TLR9 which recognize viral DNA and RNA, can lead to phosphorylation and dimerization of IRF-7 leading to IFNα/β production along with inflammatory cytokines through NF-κB and AP-1 [64, 66, 67]. The Fig. (I) illustration of TLR signaling is generalized and does not include the pathway of signaling to IRF7 through MyD88.

**NON-TLR PRRs**

Among PRRs, TLRs have been extensively researched since their initial discovery in Drosophila in the late 1990s [38, 40]. However, several other non-TLR PRRs exist and have recently received attention. Cytoplasmic PRRs include the family of Nod-like receptors (NLRs) [69] and RNA helicase receptors [47]. Other non-TLR PRR include Triggering Receptors Expressed on Myeloid Cells (TREM) [70], and C-type Lectin Receptors (CLRs) [71]. NLRs [69], are capable of detecting cytosolic bacterial proteins and can induce inflammatory responses upon activation [47, 69]. NLRs and TLRs may work together to survey intracellular and extracellular pathogens, but the exact details and interactive specific signaling pathways are not yet fully known. The cytoplasmic RNA helicase family consisting of Retinoic-acid-inducible protein-1 (RIG-1) and melanoma differentiation associated antigen 5 (MDA5) recognize several RNA viruses, especially viral genomes uncoated in the cell following infection and newly synthesized dsRNA. RIG-1 and the TLR system exert antiviral responses in a cell type specific manner, since fibroblasts and conventional DCs that are RIG-1-/- are unable to produce type 1 IFN after viral infection, whereas plas-
macytoid DCs use TLR3. RIG-1 and MDA5 contain two caspase-recruitment domains (CARDs) and recognize dsRNA with the DExD/H box helicase domain. RIG-1 recruits a CARD-containing adaptor molecule called IPS-1. IPS-1 relays the signal to the kinases TBK1 and IKKi, with the result of IRF3 and IRF-7 phosphorylation and type 1 IFN production. The RIG-1 pathway bypasses the TLR3 pathway by utilizing IPS-1 instead of TRIF, see Fig. (I) [47, 72, 73].

TREM2s act as immune modulators that can regulate the differentiation and function of MΦ and DCs as well as actively participating in amplifying the effects of inflammation [70]. When TREMs are defective, promotion of activation or amplification of inflammation leading to unnecessary innate and adaptive immune system responses could potentially occur. CLRs are an important control mechanism for innate immunity, since CLRs binding to PAMPs results in first activation and then inhibition of innate immune responses to pathogens or self [71]. Therefore, a malfunction of CLR signaling may promote inflammation due to a possible inability to properly signal the end of an innate immune response. Although not clearly determined as yet, the possibilities for synergy and cross talk between the innate TLR and non-TLR PRRs should enhance the potential to perpetuate and induce an adaptive immune response. Malfunctions in any of these innate systems or receptors, especially those responsible for amplifying or regulating an inflammatory response, could potentially trigger adverse and possibly detrimental immune responses leading to pathogenesis and disease.

**PRR AND DISEASE**

Activation of the innate immune system acts as a prerequisite for the induction of an adaptive immune response [39, 56, 57]. As discussed previously, TLRs can recognize and bind both non-self and self antigens [38, 40, 47, 49, 55-57]. Binding of a TLR is associated with production of pro-
inflammatory cytokines and mediators [38, 62, 64, 67]. This is the normal response expected to a non-self microbial infection. However, PRRs capable of interacting with self antigens may have the ability to break central tolerance and prime the adaptive immune system through cytokine and inflammatory signals to become auto-reactive toward self-antigens, thus ultimately controlling the progression to autoimmunity [74, 75]. Furthermore, the production of an uncontrolled inflammatory response could lead to inflammatory disease.

Besides their beneficial role in host defense, PRRs including TLRs have been implicated in a growing number of autoimmune and inflammatory diseases. Upregulated TLR4 expression is associated with pathogenicity in inflammatory bowel disease [76]. In Crohn’s Disease, innate immune responses to bacterial flagella via TLR5-flagellin binding may actually promote an adjuvant-like effect on the adaptive immune system, thus prompting uncontrolled inflammatory responses resulting in autoimmunity [77]. Furthermore, polymorphisms in the PRR Nod2, leading to either strong activation or negative attenuation of NF-κB signaling, could be an underlying factor in the pathogenesis of Crohn’s disease [78]. In atherosclerosis, an inflammatory disease and a secondary complication of diabetes, TLR4 function affects the initiation and progression of disease, (reviewed in [79]). TLR4 is expressed on MØs in lipid-rich atherosclerotic plaques and TLR4 expression can be upregulated by oxidized low-density lipoprotein [80, 81]. Patients with hyporesponsiveness to LPS, due to a TLR4 polymorphism, are protected from carotid artery atherosclerosis [82-85]. Furthermore, it has been shown that single nucleotide polymorphisms (Asp299Gly and Thr399Ile) of TLR4 are associated with reduced incidence of diabetic neuropathy in T2D [45].

TLRs committed to nucleic acid recognition have also been implicated in autoimmune disease. RNA released from necrotic synovial fluid can activate synovial fibroblasts in human rheumatoid arthritis via TLR3 [60]. Non-specific stimulation of TLR3 with Lymphoproliferative Choriomeningitis virus (LCMV) can precipitate autoimmune hepatitis. LCMV stimulates production of type 1 IFNs and TNFα from APC, resulting in chemokine production in liver tissue causing chemotaxis of antigen specific CD8⁺ T cells ultimately leading to whole organ liver destruction [86]. Antibodies to RNA and DNA-containing autoantigens are characteristic of the autoimmune disease systemic lupus erythematosus (SLE). TLR7 in B cells is required to generate autoantibodies to RNA antigens in vivo, while TLR9 is required for efficient production of antibodies to relevant DNA autoantigens in SLE [87]. The interaction of TLRs 3, 7, 8 or 9 with self-DNA, RNA, or nucleotide complexes has been proposed as an initiating trigger for the development of autoimmunity, termed the toll hypothesis [74].

TLRs AND T1D

Cell surface expression, as well as mRNA for TLR2 and TLR4, is significantly increased in T1D patients compared to non-diabetics. Signaling molecules MyD88, TRIF, phosphorylated IL-1 receptor-associated kinase, and NF-κB were upregulated and increased production of cytokine products IL-1β and TNFα was observed [88]. Previously, a link between T1D and elevated levels of TNFα, by human mononuclear cells, was reported [89] in Danish males. Furthermore, recently diagnosed T1D patients display significantly increased levels of TNFα, IL-2, IFNγ, and other proinflammatory cytokines in their peripheral blood [90]. Therefore, TLR2 and TLR4 expression is increased in human T1D and may contribute to a proinflammatory state.

Increased TLR expression, upregulated NF-κB, and overexpression of TLR4-induced proinflammatory cytokines TNFα, IL-12, and IL-6, in correlation with a significant decrease in regulatory cytokine IL-10, was observed at the onset of diabetes in the NOD mouse [91]. Similar TLR expression levels and TLR-induced proinflammatory cytokines have been observed in T2D mouse models reliant on elevated glucose levels and MAPK [92]. These observations may be reflective of a hyperglycemic state since a study by Kaizer et al. [93] showed similar increased expression levels of genes, especially IL-1β and c-myc in peripheral blood mononuclear cells obtained from both T1D and T2D patients. Furthermore, diabetic patients in a hyperglycemic crisis have elevated plasma levels of IL-1β, TNFα, IL-6 and IL-8, all pro-inflammatory cytokines [94]. However, hyperglycemia cannot be the full explanation for dysregulated cytokines since non-diabetic healthy family members of patients with T1D exhibit an overproduction of a number of cytokines that are implicated in diabeticogenesis and further, the abnormalities did not correlate with islet cell autoantibodies or HLA-DR phenotype [95].

The importance of particular TLRs has been studied by utilizing TLR knock out (KO) mice on an NOD background and examining diabetes rates. Kim et al. [96] have proposed that TLR2 contributes to the initiation of autoimmune diabetes by sensing apoptotic beta cells undergoing secondary necrosis. Furthermore, the development of diabetes was markedly reduced in TLR2⁻/⁻ KO mice, whereas TLR4⁻/⁻ KO mice were unaffected. The authors propose that a TLR2-dependent activation of antigen presenting cells allows priming of diabetogenic T cells leading to autoimmunity [96]. Recent work by Wen et al. [97] supports the concept that TLR4 is not involved in diabetes development. In contrast however, using two independently derived TLR2 KO NOD mouse lines, the individual loss of TLR2 did not have any effect on the spontaneous rate of diabetes development [97]. Interestingly, in a Korean study, a single nucleotide polymorphism (SNP) in TLR2, known as TLR2-H4, correlated with T1D in that having more than one copy of TLR2-H4 was associated with strong protection against developing T1D [41]. Based on these studies TLR4 may not be involved in T1D development, while the exact role of TLR2 is questionable.

Knocking out expression of MyD88, the adapter protein responsible for most TLR signal transduction, protected NOD mice housed in specific pathogen free (SPF) conditions from the development of diabetes [97]. However, when the MyD88 KO NOD mice were re-derived as germ free, autoimmune diabetes was rampant [97]. It was determined that intestinal bacteria normally present in the gut, but lacking in the germ-free state, actually protects NOD mice from diabetes development. In fact, antibiotic treatment of the MyD88 KO NOD mice lowered resistance to diabetes development in the SPF conditions. Early work showed that treatment of NOD mice with complete Freund’s adjuvant (CFA), contain-
ing mycobacteria, prevented diabetes [98, 99]. Furthermore, live attenuated *Salmonella typhimurium*, a gut pathogen, is able to halt diabetes in a wide age range of NOD mice by generating immunomodulatory DCs [100]. A very interesting point in the Wen study [97] is that the intestinal microbiota were able to protect in a MyD88 independent manner. This should also rule out other TLRs that signal through MyD88, such as TLR5. However, intracellular pattern recognition receptors should be examined for involvement in protection, such as NLRs that can recognize intracellular invasion by bacteria or the intracellular presence of bacterial products. Stimulation of Nod1 or Nod2 can lead to an inflammatory response through NF-κB [reviewed in (69)]. These results also support the hygiene hypothesis [101] wherein introduction of hygienic measures reduces the amount of exposure to microbial agents and concomitantly lowers risk of infection. However, such environmentally clean conditions favor diabetes development in genetically susceptible animal models [102, 103]. Inversely, early exposure to microbial antigens modulates macrophage function [104] resulting in downregulation of cellular autoaggression against islet beta cells [105]. TLR stimulation may be involved in this phenomenon since T1D is prevented in NOD mice by treatment with LPS or TLR4 agonists [106] and by the TLR9 agonist, CpG [107].

Potential viral triggers of T1D include Adenovirus, Cox-sackie B virus, Cytomegalovirus, Hepatitis C virus, Mumps virus, and the Rubella virus [108-111]. TLR3 is known to recognize viral intermediate dsRNA and its mimic poly(I):poly(C) [38, 40, 67], and therefore, has received attention as a possible link in the development of T1D and autoimmunity. TLR3 activation leads to the production of type 1 IFNs, which are key cytokines that induce an antiviral state in target cells, as well as serve to activate APCs and effect adaptive immunity by stimulating CD8 memory T cells (reviewed in [68, 112]). Bone marrow-derived Mø at the onset of diabetes in the NOD mouse express significantly higher basal levels of TLR3 than that of pre-diabetic NOD mice and control strains [91] and stimulation with poly(I):poly(C), elicited a nine-fold increase in production of type 1 IFNs in diabetic animals compared to non-diabetic controls [91]. Furthermore, TLR-3 expression in islets may be partially responsible for diabetes development in rat insulin promoter-B7.1 transgenic BALB/c mice when diabetes is precipitated with poly(I):poly(C) and insulin B9-23 peptide [42].

A recent report indicated that loss of TLR3 expression has no effect on the development of diabetes in the NOD mouse [97]. However, following viral infection, dsRNA intermediates or dsDNA, in the cytosol, can signal triggering of transcription leading to type 1 interferons by binding intracellular pattern recognition receptors, RIG-I or MDA5, thus bypassing TLR3 [68]. In fact, type 1 IFN gene induction is still observed in cells from TLR3−/− mice after stimulation with poly(I):poly(C) (reviewed in [68]). Viral induction of type 1 IFN has been implicated in T1D development, although it has not been proven [113]. However, IFNα therapy can lead to the production of islet autoantibodies and IFNα is detected by histological analysis in the pancreata of patients with T1D, (reviewed in [113]). Autoimmune diabetes can be induced when IFNα is expressed as a transgene in islets of mice not genetically susceptible to the disease [114]. Furthermore, treatment of β-cells with poly(I):poly(C), in combination with IFN-α, -β or -γ significantly increases apoptosis [115]. Most importantly, a genome-wide association study of nonsynonymous SNPs identified the interferon-induced helicase (IFIH1) region as a susceptibility locus for T1D in humans. IFIH1 is also known as MDA5 [9]. Therefore, the involvement of RIG-1 and/or MDA5 in the development of T1D still needs to be assessed.

Involvement of nucleotide sensing TLRs in diabetes development has been studied in the Biobreeding diabetes-resistant rat (BBDR). Treatment with TLR3 ligand poly(I):poly(C), and the elimination of ART2+ regulatory T cells, results in a 100% diabetes rate [116]. Treatment with diabetogenic Kilham rat virus (KRV) results in approximately a 30% incidence of diabetes. The KRV acts as a TLR9 ligand and upregulates proinflammatory genes. KRV can synergize with other agonists of various TLRs or whole heat killed bacteria (Escherichia coli or Staphylococcus aureus) to induce a 50-100% diabetes rate depending on the co-TLR agonist used. Therefore, in the BBDR rat model, the TLR9-signaling pathway is involved KRV-induced autoimmune diabetes [117, 118]. An individual role for TLR9 in spontaneous type 1 diabetes development in the NOD mouse has yet to be determined.

In summary, the TLR system is in place to protect the host against unwanted pathogenic microbes. However, TLRs triggered by self-ligands or inflammatory molecules, such as type 1 IFNs, could promote an unwarranted immune response which in turn, could non-specifically activate T cells through cytokine or inflammatory signals. Loss of down-regulation or chronic stimulation could exacerbate the problem and lead to cellular and, ultimately, tissue or organ destruction.

**TLRs AND T2D**

Several studies in the 1990s suggested a relationship between obesity and inflammation [31, 119-122]. These studies showed that type 2 diabetic patients and/or animal models had increased serum levels of acute-phase reactants and that TNFα was increased in adipose tissue in obese rodents. Importantly, when TNFα action was blocked, insulin sensitivity improved [31]. The link between inflammatory cytokines of the innate immune system, such as TNFα, IL-1β, MCP-1, and IL-6, and obesity is now firmly established [26, 27, 30, 35]. Therefore, obesity and type 2 diabetes are considered to be low-grade inflammatory diseases (reviewed in [26, 27, 29, 30, 33, 35, 123, 124]).

Once cytokines are implicated in disease pathology, TLR involvement needs to be explored. Cell types involved in obesity, such as adipocytes and Mφs, are known to express TLR2 and TLR4 [58, 125-128]. Obese *db/db* mice have greater mRNA levels of TLR4 in epididymal fat pads, compared to *db/+* littersmates [128]. Separation of whole, white adipose tissue into adipocyte and SVC fractions revealed that the increased TLR4 expression resided with the adipocytes [128]. TLR4 mRNA expression is also increased in diet induced obese WT, *ob/ob*, and *db/db* mice in comparison to controls [127]. Furthermore, the TLR4 is functional as determined by LPS stimulation and resultant IL-6 production.
complications of diabetes [132-134]. Macrophage and other
response to infection may underlie the
Diabetes is often complicated by acute or chronic infec-
firmed.
TLR4 mutation does not affect M
inflammatory processes decrease and insu-
Therefore, inflammatory processes decrease and insu-
Evidence from cell culture and animal tissue studies sup-
sequences of TNFα and IL-6 mRNA are seen in response to
TLR4 interference of any kind reduces FFA-induced signaling and
Studies using TLR4 knock-out or C3H/HeJ mice with a
and Defective LPS Responsiveness, have proven extremely useful in understanding the role of
Importantly, TLR4−/− and TLR4 defective mice, fed a high fat
developed increased feeding efficiency, increased meta-
tissue concentrations of TNFα, IL-6, and, in one case, serum FFA
to control mice [126, 130, 131]. Surprisingly, there was no significant difference between the TLR4-
defective mouse and control strains for Φ infiltration in
adipose after a 16 week high fat diet [126] suggesting that
TLR4 mutation does not affect Φ infiltration. Studies re-
ported increases in adipose and skeletal muscle insulin sensi-
tivity. Therefore, inflammatory processes decrease and insu-
inulin sensitivity improves in diet-induced obesity and cells
with free fatty acids when TLR4 is either not present or not fully functional. Thus, TLR4 does appear to play a
role in T2D, while involvement of TLR2 is still uncon-
firmed.

DIABETES AND INFECTIOUS DISEASE

Diabetes is often complicated by acute or chronic infec-
tion, and diminished responses to infection may underlie the
complications of diabetes [132-134]. Macrophage and other
innate immune system cells also play a key role in inflamma-
tory and immune mediated disease complications [135].
Diabetics are at severe risk to develop periodontitis [136].
A high prevalence of Helicobacter pylori infection is correlated with dyspeptic symptoms in T2D patients [137].
An increased liver fibrosis stage and faster fibrosis progression rate is the consequence of the association between diabetes and hepatitis C virus infection (reviewed in [138]). In India, tuberculosis occurs at a rate 2-5 times higher in diabetics compared to the general population [139]. Staphylococcus aureus multiplies in the blood of diabetic mice with hyper-
glycemia due to diminished leukocytic respiratory burst [140]. Polymicrobial infections were significantly more severe in diabetic mice, exhibiting a 5 to 35 times increase in the number of colony forming units compared to control
mice [141]. An accelerated form of atherosclerosis is associ-
ated with diabetes and cytomegalovirus infection [142].
Coxackievirus-B4 can trigger cytokine production through
TLR4 in human pancreatic cells [143]. Furthermore, vascular inflammation, a common complication in both T1D and
T2D, is the result of infectious load [144-146]. Diabetes
complications affect many different organs systems and al-
ter inflammatory responses and impaired responses to in-
fec tion are observed. Therefore, diabetes has been classified as a secondary immune deficiency disorder [132-134].

Neither diminished nor exaggerated signaling through
TLR would be beneficial to the host. The inability to resolve chronic infection by pathogenic organisms leads to chronic
stimulation of macrophages. Products of macrophages, such as nitrogen and oxygen free radicals, TNFα and prostaglan-
din 2 (PGE2), can damage soft tissue and active osteoclasts
to resorb bone in periodontitis [136]. Monocytes from dia-
etic patients are capable of secreting proinflammatory cyto-
kines (TNFα, IL-1β and PGE2) in an exaggerated fashion, compared to controls, in response to Porphyromonas gingivalis, a know periodontal pathogen [147, 148]. Therefore, diabetes can respond to an equivalent oral bacterial burden with inappropriate inflammatory responses leading to severe periodontitis [147, 148].

A major question is whether all diabetics are prone to
developing infections because there is a problem with the
innate immune system and TLRs. Hyperglycemia in diabetes
is associated with the synthesis of proinflammatory cytoki-
nes during infection [149]. High glucose induces multiple
proinflammatory cytokines and chemokines in monocytes,
cells that are involved in the secondary complications of
diabetes [150]. Diabetic patients in a hyperglycemic crisis have elevated plasma levels of IL-1β, TNFα, IL-6, IL-8, re-
active oxygen species (ROS), and cardiovascular risk factors [94]. Human peripheral blood cells activated by high glucose
via oxidant stress express increased levels of TNFα and NF-
κB [151]. Activated monocytes that adhere to endothelium play a key role in inflammatory and cardiovascular diseases. Alternately, the reduction of glucose levels below 200 mg/dl improves granulocyte adherence and granulocytosis, key elements of the innate immune system in the defense against infectious microorganisms. TLR4 sensitivity in the diabetic state is a factor that underlies the increased risk of certain
vascular complications in diabetes [44]. In NOD mice,
macrophages differentiated from stem cells under hypergly-
cemic conditions have increased expression of TLR2, TLR4,
and TNFα. Furthermore, stimulation of TLRs at the onset of diabetes leads to exaggerated inflammatory responses to bacterial and viral ligands [91]. The overproduction of proinflammatory molecules could lead to chronic inflammation and impaired, or inappropriate, responses to infectious pathogens in diabetes, due in part to the altered TLR responsiveness of diabetic macrophages.

The growing evidence for a role of the innate immune system in autoimmune diabetes, inflammatory diseases, and diabetic complications warrants a more detailed investigation of TLR expression and signaling in macrophages and dendritic cells. Modulation of the expression, responsiveness, and signaling of TLRs in the prediabetic state leading to diabetes, and in the diabetic state itself, will have an affect on the inflammatory environment and, consequently, islet transplantation, the ability to repair wounds, resolution of infection without tissue damage, and the progression to complications [152-155].

CONCLUSION

The immune system has developed to sustain the health of the host and protect against foreign invaders. However, in instances such as autoimmunity and inflammatory diseases, a dysregulated immune response could contribute directly, or indirectly, to pathogenesis of disease. We have reviewed the proposed roles of TLR and other innate immune components in the pathogenesis of T1D and T2D. Presently, and in the near future, along with expanding the knowledge of basic TLR function and signaling, research should focus on manipulating TLR ligands and signaling molecules to treat or prevent disease. Certainly enough is known to begin the process of developing small molecule antagonists, targeting treatment to diseased organs such as the pancreas and the adipose tissue, and specific neutralization of inflammatory cytokines for clinical applications testing.

ABBREVIATIONS

TLR = Toll-like Receptor
MΦ = Macrophages
MHC = Major histocompatibility complexes
PAMPs = Pathogen Associated Molecular Patterns
PRRs = Pattern Recognition Receptors
MyD88 = Myeloid differentiation factor 88

ACKNOWLEDGEMENTS

This review article on innate immunity is dedicated to the memory of Dr. Charles A. Janeway Jr, mentor. This work was supported by the United States Department of Agriculture/Cooperative State Research, Education and Extension Service grant 2008-38903-19049 (MFM), by the National Institute for Dental and Craniofacial Research R21DE014486 (MFM), and the National Institutes of Health grants R01 DK53456 and R01 DK56200 (MP).

REFERENCES

Innate Immunity, Toll-Like Receptors, and Diabetes

Current Immunology Reviews, 2009, Vol. 5, No. 2 119

[27] Bastard JP, Mauchi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006; 17: 4-12.


Kolb H, Elliott R. Increasing incidence of IDDM a consequence of
Hussain M, Maher J, Warnock T
Kiehle FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflamma-
Ameziane N, Beillat T, Verpillat P, et al. Association of the toll-
Kiechle S, Wiedermann C, et al. Toll-like receptor 4 and 
liver is controlled by Toll-like receptor 3. J Clin Invest 2006; 
116: 2456-63.
Christensen SR, Shupe J, Nickerson K, et al. Toll-like receptor 7 and 
TLR9 dictate autoantibody specificity and have opposing in-
flammatory and regulatory roles in a murine model of lupus. Immu-

Devaraj S, Dasu MR, Rockwood J, et al. Increased toll-like recep-
tor (TLR) 2 and TLR4 expression in monocytes from patients with 
type 1 diabetes: further evidence of a proinflammatory state. J Clin 
Endocrinol Metab 2008; 93: 578-83.
Pociot F, Briant L, Jongeneel CV, et al. Association of tumor ne-
crosis factor (TNF) and class II major histocompatibility complex alleles 
with the secretion of TNF-a and TNF-b by human mononu-
clear cells: a possible link to insulin-dependent diabetes mellitus. 

Hussain M, Peakman M, Gallati H, et al. Elevated serum levels of 
macrophage derived cytokines precede and accompany the onset of 

Mammad MK, Morran M, Slotterbeck B, et al. Dysregulated Toll-
like receptor expression and signaling in bone marrow-derived 
macrophages at the onset of diabetes in the non-obese diabetic 

Sherry CL, O'Connor JC, Kramer JM, Freund GG. Augmented lipopolysaccharide-induced TNF-alpha production by peritoneal 
macrophages in type 2 diabetic mice is dependent on elevated glu-

Kaizer EC, Glaser CL, Chassabel D, et al. Gene expression in 
peripheral blood mononuclear cells from children with diabetes. J 

Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflamma-
tory cytokines, markers of cardiovascular risks, oxidative stress, 
and lipid peroxidation in patients with hyperglycemic crises. Dia-
betes 2004; 53: 2079-86.

Hussain M, Maher J, Warnock T, et al. Cytokine overproduction in 
healthy first degree relatives of patients with IDD. Diabetologia 1999; 
41: 343-9.

Kim HS, Han MS, Chung KW, et al. Toll-like receptor 2 senses beta-
cell death and contributes to the initiation of autoimmune dia-

455: 1109-13.

McInerney M, Pek S, Thomas D. Prevention of insulinitis and dia-
betes onset by treatment with complete Freund’s adjuvant in NOD 

Sadelain M, Qin H, Lauzon J, Singh B. Prevention of type I dia-
betes in NOD mice by adjuvant immunotherapy. Diabetes 1990; 

Raine T, Zacccone P, Mastroeni P, Cooke A. Salmonella typhi-
murium infection in nonobese diabetic mice generates immune-
modulatory dendritic cells able to prevent type 1 diabetes. J Immu-
2006; 177: 2242-33.

Kolb H, Elliott R. Increasing incidence of IDDM a consequence of 

Like A, Guberski D, Butler L. Influence of environmental viral 
agents on frequency and tempo of diabetes mellitus in BB/Wor 

Wilberz S, Partke HJ, Dagnanes-Hansen F, Herberg L. Persistent 
MHV (mouse hepatitis virus) infection reduces the incidence of 
34: 2-5.
Innate Immunity, Toll-Like Receptors, and Diabetes


